Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6426762 | 0.91 | AKR1C3 (0.40) | AKR1C3AKR1C2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6425995 | 0.90 | MEN1 (0.39) | AKR1C3AKR1C2CNR1CNR2MEN1 | |
| SCHEMBL6423898 | 0.90 | MEN1 (0.39) | AKR1C3AKR1C2CNR1CNR2MEN1 | |
| SCHEMBL6423915 | 0.89 | MEN1 (0.34) | AKR1C3AKR1C2CNR1CNR2MEN1 | |
| SCHEMBL6425335 | 0.89 | AKR1C3 (0.42) | AKR1C3AKR1C2MEN1KMT2APTGS1 | |
| SCHEMBL6423604 | 0.88 | MEN1 (0.36) | AKR1C3AKR1C2CNR1CNR2MEN1 | |
| SCHEMBL6425357 | 0.88 | MEN1 (0.36) | AKR1C3AKR1C2CNR1CNR2MEN1 | |
| SCHEMBL6423793 | 0.88 | ABCB11 (0.35) | AKR1C3AKR1C2PTGS1PTGS2 | |
| SCHEMBL6425694 | 0.88 | CNR1 (0.35) | AKR1C3AKR1C2CNR1CNR2MEN1 | |
| SCHEMBL6425828 | 0.88 | AKR1C3 (0.34) | AKR1C3AKR1C2MEN1KMT2APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | AKR1C3 577/4885AKR1C2 563/4885CNR1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.